At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 111 enrolled
Drug / intervention
Ofatumumabdrug
Likely dose
Ofatumumab 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-arm, Prospective, Multi-center Study to Explore Maintained Efficacy With Ofatumumab Therapy in Patients With Relapsing Multiple Sclerosis Who Discontinue Intravenously Delivered Anti-CD20 Monoclonal Antibody (aCD20 mAb) Therapy (OLIKOS)
In Brief
A Phase 3 clinical trial evaluating Ofatumumab for Relapsing Multiple Sclerosis. Completed, enrolled 111 participants across 20 sites in 2 countries.
Detailed Summary
A single arm study evaluating the continued efficacy, safety and tolerability of ofatumumab in patients with relapsing multiple sclerosis who are transitioning from aCD20 mAb therapy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsing Multiple Sclerosis
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartOct 2020
Primary CompletionNov 2023
Study CompletionOct 2024
TodayJul 2026
First PostedJul 27, 2020
Enrollment StartOct 19, 2020
Primary CompletionNov 20, 2023
Study CompletionOct 21, 2024
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 5.9 years ago
Interventions
Ofatumumabdrug
Investigational drug will be provided in an autoinjector for subcutaneous administration containing 20 mg ofatumumab (20 mg/0.4 ml)